Herbert Kim Lyerly, MD



email this

Professor of Surgery
Assistant Professor in Immunology
Associate Professor of Pathology
Department / Division:
Surgery / Surg Sci Applied Therapeutics Section
DUMC 2606
Durham, NC 27710
Office Telephone:
  • MD, University of California–Los Angeles David Geffen School of Medicine, 1983
  • Surgery, Duke University Medical Center, 1984-1985, 1987-1990
  • Research, Duke University Medical Center, 1985-1987
Clinical Interests:
Surgical treatment of breast cancer; gene- and immune-based therapy for breast, kidney, lung, colon, and pancreatic cancers
Representative Publications:
  • Clay, TM; Morse, M; Lyerly, HK. Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenes. Expert Opinion on Biological Therapy. 2002;2:353-360.  Abstract
  • Keilholz, U; Weber, J; Finke, JH; Gabrilovich, DI; Kast, WM; Disis, ML; Kirkwood, JM; Scheibenbogen, C; Schlom, J; Maino, VC; Lyerly, HK; Lee, PP; Storkus, W; Marincola, F; Worobec, A; Atkins, MB. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. Journal of Immunotherapy. 2002;25:97-138.  Abstract
  • Morse, MA; Nair, SK; Boczkowski, D; Tyler, D; Hurwitz, HI; Proia, A; Clay, TM; Schlom, J; Gilboa, E; Lyerly, HK. The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. International Journal of Gastrointestinal Cancer. 2002;32:1-6.  Abstract
  • Morse, MA; Lyerly, HK; Li, Y. The role of IL-13 in the generation of dendritic cells in vitro. Journal of Immunotherapy. 1999;22:506-513.  Abstract
  • Morse, MA; Vredenburgh, JJ; Lyerly, HK. A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy. Stem Cells and Development. 1999;8:577-584.  Abstract